Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  ICON Public Limited Company    ICLR   IE0005711209


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ICON Public : Appoints New Chief Medical Officer

05/05/2020 | 04:31am EST

ICON announces the appointment of Dr. Kristen K. Buck as the new Chief Medical Officer (CMO)

ICON plc, (NASDAQ: ICLR) a leading global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Dr. Kristen K. Buck has been appointed Chief Medical Officer.

Kristen joins ICON from Optum Insights (part of the United Healthcare group) where she was SVP & Chief of Clinical Development. Kristen led the clinical operations and regulatory groups to create a Real-World Evidence and Outcomes clinical trial business. Her experience ranges over multiple therapy areas including GI, neuroscience, dermatology, ophthalmology, oncology, cardiovascular/metabolic, immunology, renal, women’s health, orphan diseases, liver, and psychiatry.

Kristen is a board certified and licenced physician from the Pennsylvania State University School of Medicine, and completed her Internship and Residency in Internal Medicine at Abington Memorial Hospital, before working as a primary care practitioner in a private practice. From there Kristen moved to the FDA in the GI and Hematology division, where she was responsible for reviewing efficacy and safety for all new indications, as well as post-marketing safety for over 40 drugs. Kristen spent time working at AstraZeneca in clinical development and in its Innovative Medicines group.

“We are delighted to appoint Dr Kristen Buck as our new Chief Medical Officer,” said Steve Cutler, ICON’s Chief Executive Officer. “Kristen’s appointment will improve coordination and access to the significant medical and scientific resources and expertise we have at ICON. We will focus this expertise on helping our customers negotiate challenges, as we constantly strive to improve our services and respond to the latest issues and developments in science and medicine.”

“I’m excited to be leading ICON’s position on clinical development trends, and reviewing and advising on our medical risks as the world wrestles with the Covid-19 pandemic,” said Dr. Buck. “Patient centricity is ever more important in the current climate and I look forward to working with the wider ICON team to broaden our insights and expand our expertise.”

About ICON plc

ICON plc is a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 98 locations in 40 countries and has approximately 15,100 employees as of March 31, 2020. Further information is available at www.iconplc.com.

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.


© Business Wire 2020
01/12ICON PUBLIC : plc Presentation
01/07ICON PLC : to Present at the 39th Annual JP Morgan Healthcare Conference
01/04ICON PUBLIC : Supports Pfizer and BioNTech on the Investigational COVID-19 Vacci..
2020ICON PUBLIC : Releases First Environmental, Social and Governance Report
2020ICON PLC : to Present at the 29th Annual Credit Suisse Virtual Healthcare Confer..
2020ICON PUBLIC : plc Q3 2020 Presentation
2020ICON PUBLIC : Reports Third Quarter 2020 Results
2020ICON PUBLIC : BARDA reselects ICON as preferred partner to help strengthen US em..
2020ICON PUBLIC : Wins Best CRO at the Vaccine Industry Excellence Awards
2020ICON : Launches Accellacare a Global Clinical Research Network Focused on Increa..
More news
Financials (USD)
Sales 2020 2 789 M - -
Net income 2020 330 M - -
Net cash 2020 309 M - -
P/E ratio 2020 35,8x
Yield 2020 -
Capitalization 11 661 M 11 661 M -
EV / Sales 2020 4,07x
EV / Sales 2021 3,53x
Nbr of Employees 15 250
Free-Float 98,5%
Duration : Period :
ICON Public Limited Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ICON PUBLIC LIMITED COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 206,29 $
Last Close Price 220,96 $
Spread / Highest target 8,62%
Spread / Average Target -6,64%
Spread / Lowest Target -31,2%
EPS Revisions
Managers and Directors
Stephen A. Cutler Chief Executive Officer & Executive Director
Ciaran Murray Executive Chairman
Brendan Brennan Chief Financial Officer
Tom O'Leary Chief Information Officer
Anthony J. Japour Medical Director
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.19.79%49 519
LONZA GROUP AG4.32%49 499
CELLTRION, INC.-13.09%38 562
SEAGEN INC.8.94%34 515